Privium Fund Management B.V. Has $4.85 Million Position in Zai Lab Limited (NASDAQ:ZLAB)

Privium Fund Management B.V. decreased its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 14.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 185,062 shares of the company’s stock after selling 30,562 shares during the period. Zai Lab makes up about 1.1% of Privium Fund Management B.V.’s portfolio, making the stock its 20th largest position. Privium Fund Management B.V. owned approximately 0.17% of Zai Lab worth $4,847,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. US Bancorp DE raised its holdings in shares of Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after acquiring an additional 5,534 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Zai Lab during the 3rd quarter worth approximately $225,000. Daiwa Securities Group Inc. increased its holdings in Zai Lab by 4,851.8% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock worth $231,000 after purchasing an additional 9,364 shares in the last quarter. RBF Capital LLC purchased a new stake in shares of Zai Lab in the third quarter worth approximately $241,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zai Lab by 15.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock valued at $290,000 after purchasing an additional 1,502 shares in the last quarter. 41.65% of the stock is owned by institutional investors.

Insider Activity

In other Zai Lab news, insider Frazor Titus Edmondson III sold 14,544 shares of the business’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $32.98, for a total value of $479,661.12. Following the sale, the insider now directly owns 14,328 shares in the company, valued at $472,537.44. The trade was a 50.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00. Following the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at $17,032,212.99. This represents a 9.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 122,127 shares of company stock valued at $4,024,442 in the last three months. Company insiders own 13.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a research report on Tuesday, March 4th. Bank of America reiterated a “neutral” rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. JPMorgan Chase & Co. raised their price target on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, March 13th. Finally, Scotiabank assumed coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price objective for the company.

Zai Lab Trading Down 1.1 %

ZLAB stock opened at $37.92 on Wednesday. The stock has a market cap of $4.16 billion, a P/E ratio of -13.69 and a beta of 1.08. The stock’s fifty day simple moving average is $29.97 and its two-hundred day simple moving average is $27.45. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $39.61.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The company had revenue of $109.07 million during the quarter, compared to analysts’ expectations of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. As a group, analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.